子宫颈人乳头状瘤病毒检测和治疗的实验研究
|
摘要
目的:
1.评价杂交捕获二代和流式荧光杂交技术在子宫颈人乳头状瘤病毒(HumanPapillomavirus,HPV)感染检测及宫颈病变诊治中的应用价值。
2.探讨中药保妇康栓及主要成分莪术油对HPV16的抑制作用。
方法:
1.选择在中日友好医院妇产科宫颈病变诊治中心行宫颈癌筛查的细胞学诊断异常的患者(≥ASC-US)872例,采用杂交捕获二代(HC-Ⅱ)进行13种高危型HPV的检测,同时对组织病理学≥CIN2者采用流式荧光杂交HPV分型检测法进行15种HPV亚型分型检测,比较不同方法检测结果的一致性;按宫颈组织病理学结果分为NILM组、宫颈上皮内瘤变(CIN)Ⅰ、Ⅱ、Ⅲ、宫颈癌组。以组织病理学诊断为金标准,评价高危型HPVDNA检测在宫颈病变诊断中的应用价值。采用Spearman等级相关分析HPV病毒载量与宫颈病变级别的关系。计算各HPV亚型在不同病理级别组中的阳性率。
2.以含保妇康栓的培养基体外培养宫颈癌细胞系CaSki和宫颈永生化细胞系H8,以含莪术油的培养基体外培养宫颈癌细胞系SiHa、CaSki和H8,观察药物作用后细胞形态学变化;采用四甲基偶氮唑蓝比色法(MTT)、流式细胞术检测不同浓度药物对细胞增殖的影响;应用逆转录-聚合酶链反应技术(ReverseTranscriptase Polymerase Chain Reaction,RT-PCR)检测人乳头状瘤病毒HPV16亚型E6E7mRNA的表达。
结果:
1.HC-Ⅱ法诊断宫颈高度病变(≥CIN2)的灵敏性、特异性、阳性预告值、阴性预告值分别为93.1%、66.8%、59.9%、94.8%。HC-Ⅱ阳性的ASC-US和ASC-H患者中宫颈高度病变的检出率为28.9%、30.0%,阴性者中检出率为2.3%.3.7%(P＞0.05)。NILM组HPV病毒载量与CIN以及宫颈癌组有显著性差异(P＜0.05),CIN以及宫颈癌组HPV病毒载量无显著性差别(P＞0.05)。流式荧光杂交与HC-Ⅱ两种方法对高危型HPV感染的检出结果总符合率92.4%,kappa值0.623。流式荧光杂交HPV检测结果显示≥CIN2患者最常见的基因型为16、18、52、58、31。HPV16阳性率随病变级别的增加迅速上升。CINⅡ组常见HPV亚型16、52、11、18、58、56/66,CINⅢ组常见HPV亚型16、58、18、52、31,宫颈癌组常见亚型16、18、11、31、52、58。
2.不同浓度的保妇康栓可以抑制宫颈癌细胞系Caski和宫颈永生化细胞H8的增殖;在保妇康栓作用下,Caski细胞G1期减少(P＜0.05),G2、S期增加(P＜0.05),Caski细胞凋亡率高于对照组(P＜0.05),而对H8细胞周期和凋亡率影响不明显;两种细胞系HPV16E6E7基因片段mRNA表达均明显低于对照组(P＜0.01),无剂量依赖关系。
3.不同浓度的莪术油可以抑制细胞的增殖,莪术油作用于SiHa细胞,G1期细胞减少(P＜0.05),G2、S期细胞增加(P＜0.01),细胞阻滞于G2、S期。莪术油作用于CaSki、H8细胞,G1期细胞减少(P＜0.01),S期细胞增加(P＜0.01),使细胞阻滞于S期。加药组SiHa、CaSki和H8细胞凋亡率高于对照组,有统计学差异(P＜0.01,P＜0.01,P＜0.05);三种细胞HPV16E6E7基因片段mRNA表达均明显低于对照组(P＜0.01)。
结论:
1.随着宫颈细胞学和组织病理学级别的升高,高危型HPVDNA的感染率呈趋势性升高。高危型HR-HPVDNA检测对于ASC-US有分流作用,对于ASC-H的分流作用有待进一步探讨。HC-Ⅱ法检测HR-HPV病毒载量与CIN以及宫颈癌发生有关,但与宫颈病变的严重程度无关。流式荧光杂交技术与HC-Ⅱ检测结果一致性好,是有效的HPV分型检测方法。HPV16、18、52、58、31是≥CIN2患者最常见的5种HPV感染亚型。
2.保妇康栓及其主要成分莪术油可抑制宫颈癌细胞系SiHa、CaSki以及宫颈永生化细胞系H8增殖,其机制可能与抑制HPV16E6E7表达有关。
Objectives
1.To investigate the applicable value of Hybrid CaptureⅡ(HC-Ⅱ) and the flow fluorescent hybridization assay on human papillomavirus(HPV) detecting.To evaluate the clinical accuracy of the two method for the diagnosis of cervical neoplasia.To detect the most common HPV subtype in different grades of cervical lesions.
2.To investigate the mechanism of the proliferative inhibition of HPV16 by curcuma aramatica oil.
Methods
1.872 patients with abnormal cervical cytology results who accepted cervical cancer screening in China-Japan Friendship Hospital from June 2006 to April 2007 took HR-HPV testing(HC-Ⅱmethod) and all patients underwent colposcopy and biopsy..All patients were divided into five groups as NILM,CINⅠ,CINⅡCINⅢand invasive cervical cancer(ICC).Association between HR-HPV load and CINs were evaluated by Spearman rank correlation.Those with histological pathology diagnosis as cervical intraepithelial neoplasia(CIN)Ⅱor above were HPV subtyped by flow fluorescent hybridization assay.The accordance rate of the two assays was compared. The applicable value on diagnosis of cervical lesions by the two methods was evaluated according to the diagnosis of histological pathology.The infection rates of different genotypes in each group were calculated.
2.The human cervical cancer cell line-CaSki and the immortalized cervical epithelial cell-H8 were cultured with different concentration of baofukang suppository The human cervical cancer cell line-CaSki、SiHa and the immortalized cervical epithelial cell-H8 were cultured with different concentration of curcuma aramatica oil.The proliferative inhibition of different concentration of curcuma aramatica oil or baofukang suppository on cell lines was measured by methyl thiazolyl tetrazolium(MTT) assay and flow cytometry assay;The mRNA expression of HPV16 E6E7 was determined by RT-PCR semi-quantitatively.
Results
1.The sensitivity,specificity,positive predictable value and negative predictable value for CIN2 by HC-Ⅱwere 93.1%、66.8%、59.9%、94.8%,respectively.There was significant differentce between NILM and CINs or ICC,while no significant difference was observed among CINⅠ,CINⅡ,CINⅢand ICC.The total accordance rate of the flow fluorescent hybridization assay and HC-Ⅱwas 92.4%.The most common HR-HPV subtypes among patients with CIN2 or above were HPV16,18,52,58, 31.The positive rate of HPV 16 increased rapidly with the severity of the disease.The most common HPV types were 16,52,11,18,58 in CINⅡ,group,16,58,18,52,31 in CINⅢgroupand 16,18,31,52,58 in ICC group.
2.The growth of Caski and H8 was inhibited by different concentration of Baofukang suppository.After Baofukang Suppository treatment,Caski and H8 cell line showed decreased levels of HPV16 E6E7 mRNA than that in the control group.The growth of CaSki,SiHa and H8 was inhibited by different concentration of curcuma aramatica oil.SiHa cells were accumulated in G2、S phase(P＜0.01),while CaSki and H8 cells were accumulated in S phase(P＜0.01).The apoptosis rate in CaSki,SiHa and H8 cells was higher than that in control group(P＜0.01, P＜0.01,P＜0.05).CaSki,SiHa and H8 cell showed decreased level of HPV16 E6E7 mRNA than that in the control group after curcuma aramatica oil treatment(P＜0.01).
Conclusions
1.The positive rate of HR-HPV increases with the severity of the cervical lesions.HR-HPV testing is useful in triage of ASC-US,while its triage role for ASC-H need further study.The HR-HPV load is significantly associated with the presence of CINs and ICC.HPV viral load does not increase with severity of cervical neoplasia.The 5 most common subtypes in patients≥CIN2 or above are HPV16,18,52,58,31.
2.The results suggest that Baofukang Suppository and curcuma aramatica oil may execute its antiHPV activity primarily by decreasing the expression of HPV 16E6E7 in cervical cancer cell line and immortalized cervical epithelial cell.
1.评价杂交捕获二代和流式荧光杂交技术在子宫颈人乳头状瘤病毒(HumanPapillomavirus,HPV)感染检测及宫颈病变诊治中的应用价值。
2.探讨中药保妇康栓及主要成分莪术油对HPV16的抑制作用。
方法:
1.选择在中日友好医院妇产科宫颈病变诊治中心行宫颈癌筛查的细胞学诊断异常的患者(≥ASC-US)872例,采用杂交捕获二代(HC-Ⅱ)进行13种高危型HPV的检测,同时对组织病理学≥CIN2者采用流式荧光杂交HPV分型检测法进行15种HPV亚型分型检测,比较不同方法检测结果的一致性;按宫颈组织病理学结果分为NILM组、宫颈上皮内瘤变(CIN)Ⅰ、Ⅱ、Ⅲ、宫颈癌组。以组织病理学诊断为金标准,评价高危型HPVDNA检测在宫颈病变诊断中的应用价值。采用Spearman等级相关分析HPV病毒载量与宫颈病变级别的关系。计算各HPV亚型在不同病理级别组中的阳性率。
2.以含保妇康栓的培养基体外培养宫颈癌细胞系CaSki和宫颈永生化细胞系H8,以含莪术油的培养基体外培养宫颈癌细胞系SiHa、CaSki和H8,观察药物作用后细胞形态学变化;采用四甲基偶氮唑蓝比色法(MTT)、流式细胞术检测不同浓度药物对细胞增殖的影响;应用逆转录-聚合酶链反应技术(ReverseTranscriptase Polymerase Chain Reaction,RT-PCR)检测人乳头状瘤病毒HPV16亚型E6E7mRNA的表达。
结果:
1.HC-Ⅱ法诊断宫颈高度病变(≥CIN2)的灵敏性、特异性、阳性预告值、阴性预告值分别为93.1%、66.8%、59.9%、94.8%。HC-Ⅱ阳性的ASC-US和ASC-H患者中宫颈高度病变的检出率为28.9%、30.0%,阴性者中检出率为2.3%.3.7%(P＞0.05)。NILM组HPV病毒载量与CIN以及宫颈癌组有显著性差异(P＜0.05),CIN以及宫颈癌组HPV病毒载量无显著性差别(P＞0.05)。流式荧光杂交与HC-Ⅱ两种方法对高危型HPV感染的检出结果总符合率92.4%,kappa值0.623。流式荧光杂交HPV检测结果显示≥CIN2患者最常见的基因型为16、18、52、58、31。HPV16阳性率随病变级别的增加迅速上升。CINⅡ组常见HPV亚型16、52、11、18、58、56/66,CINⅢ组常见HPV亚型16、58、18、52、31,宫颈癌组常见亚型16、18、11、31、52、58。
2.不同浓度的保妇康栓可以抑制宫颈癌细胞系Caski和宫颈永生化细胞H8的增殖;在保妇康栓作用下,Caski细胞G1期减少(P＜0.05),G2、S期增加(P＜0.05),Caski细胞凋亡率高于对照组(P＜0.05),而对H8细胞周期和凋亡率影响不明显;两种细胞系HPV16E6E7基因片段mRNA表达均明显低于对照组(P＜0.01),无剂量依赖关系。
3.不同浓度的莪术油可以抑制细胞的增殖,莪术油作用于SiHa细胞,G1期细胞减少(P＜0.05),G2、S期细胞增加(P＜0.01),细胞阻滞于G2、S期。莪术油作用于CaSki、H8细胞,G1期细胞减少(P＜0.01),S期细胞增加(P＜0.01),使细胞阻滞于S期。加药组SiHa、CaSki和H8细胞凋亡率高于对照组,有统计学差异(P＜0.01,P＜0.01,P＜0.05);三种细胞HPV16E6E7基因片段mRNA表达均明显低于对照组(P＜0.01)。
结论:
1.随着宫颈细胞学和组织病理学级别的升高,高危型HPVDNA的感染率呈趋势性升高。高危型HR-HPVDNA检测对于ASC-US有分流作用,对于ASC-H的分流作用有待进一步探讨。HC-Ⅱ法检测HR-HPV病毒载量与CIN以及宫颈癌发生有关,但与宫颈病变的严重程度无关。流式荧光杂交技术与HC-Ⅱ检测结果一致性好,是有效的HPV分型检测方法。HPV16、18、52、58、31是≥CIN2患者最常见的5种HPV感染亚型。
2.保妇康栓及其主要成分莪术油可抑制宫颈癌细胞系SiHa、CaSki以及宫颈永生化细胞系H8增殖,其机制可能与抑制HPV16E6E7表达有关。
Objectives
1.To investigate the applicable value of Hybrid CaptureⅡ(HC-Ⅱ) and the flow fluorescent hybridization assay on human papillomavirus(HPV) detecting.To evaluate the clinical accuracy of the two method for the diagnosis of cervical neoplasia.To detect the most common HPV subtype in different grades of cervical lesions.
2.To investigate the mechanism of the proliferative inhibition of HPV16 by curcuma aramatica oil.
Methods
1.872 patients with abnormal cervical cytology results who accepted cervical cancer screening in China-Japan Friendship Hospital from June 2006 to April 2007 took HR-HPV testing(HC-Ⅱmethod) and all patients underwent colposcopy and biopsy..All patients were divided into five groups as NILM,CINⅠ,CINⅡCINⅢand invasive cervical cancer(ICC).Association between HR-HPV load and CINs were evaluated by Spearman rank correlation.Those with histological pathology diagnosis as cervical intraepithelial neoplasia(CIN)Ⅱor above were HPV subtyped by flow fluorescent hybridization assay.The accordance rate of the two assays was compared. The applicable value on diagnosis of cervical lesions by the two methods was evaluated according to the diagnosis of histological pathology.The infection rates of different genotypes in each group were calculated.
2.The human cervical cancer cell line-CaSki and the immortalized cervical epithelial cell-H8 were cultured with different concentration of baofukang suppository The human cervical cancer cell line-CaSki、SiHa and the immortalized cervical epithelial cell-H8 were cultured with different concentration of curcuma aramatica oil.The proliferative inhibition of different concentration of curcuma aramatica oil or baofukang suppository on cell lines was measured by methyl thiazolyl tetrazolium(MTT) assay and flow cytometry assay;The mRNA expression of HPV16 E6E7 was determined by RT-PCR semi-quantitatively.
Results
1.The sensitivity,specificity,positive predictable value and negative predictable value for CIN2 by HC-Ⅱwere 93.1%、66.8%、59.9%、94.8%,respectively.There was significant differentce between NILM and CINs or ICC,while no significant difference was observed among CINⅠ,CINⅡ,CINⅢand ICC.The total accordance rate of the flow fluorescent hybridization assay and HC-Ⅱwas 92.4%.The most common HR-HPV subtypes among patients with CIN2 or above were HPV16,18,52,58, 31.The positive rate of HPV 16 increased rapidly with the severity of the disease.The most common HPV types were 16,52,11,18,58 in CINⅡ,group,16,58,18,52,31 in CINⅢgroupand 16,18,31,52,58 in ICC group.
2.The growth of Caski and H8 was inhibited by different concentration of Baofukang suppository.After Baofukang Suppository treatment,Caski and H8 cell line showed decreased levels of HPV16 E6E7 mRNA than that in the control group.The growth of CaSki,SiHa and H8 was inhibited by different concentration of curcuma aramatica oil.SiHa cells were accumulated in G2、S phase(P＜0.01),while CaSki and H8 cells were accumulated in S phase(P＜0.01).The apoptosis rate in CaSki,SiHa and H8 cells was higher than that in control group(P＜0.01, P＜0.01,P＜0.05).CaSki,SiHa and H8 cell showed decreased level of HPV16 E6E7 mRNA than that in the control group after curcuma aramatica oil treatment(P＜0.01).
Conclusions
1.The positive rate of HR-HPV increases with the severity of the cervical lesions.HR-HPV testing is useful in triage of ASC-US,while its triage role for ASC-H need further study.The HR-HPV load is significantly associated with the presence of CINs and ICC.HPV viral load does not increase with severity of cervical neoplasia.The 5 most common subtypes in patients≥CIN2 or above are HPV16,18,52,58,31.
2.The results suggest that Baofukang Suppository and curcuma aramatica oil may execute its antiHPV activity primarily by decreasing the expression of HPV 16E6E7 in cervical cancer cell line and immortalized cervical epithelial cell.
引文
1 Working group on the evaluation of cancer-preventive strategies. Iarc Handbooks of Cancer Prevention Vol 10:Cervix Cancer Screening. Lyon, France:IARC Press;2005
2 Blanchet JS, Sonnex C, Gough GW, et al. Local and systemic human papillomavirus type 6b-specific cellular immune responses in patients with recurrent genital warts. Viral Immunol. 2007,20(1):44-55.
3 Hagiwara M, Sasaki H, Matsuo K, et, al. Loop-mediated isothermal amplification method for detection of human papillomavirus type 6, 11, 16, and 18. J Med Viral. 2007, 79(5):605-615.
4 Gajewska M, Wielgos M, Kaminski P, et al. The occurrence of genital types of human papillomavirus in normal pregnancy and in pregnant renal transplant recipients. Neuro Endocrinol Lett. 2006 Aug;27(4) :529-534.
5 Tarkkanen J, Auvinen E, Nieminen P, et al. HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland.Acta Obstet Gynecol Scand. 2007;86(3):367-372.
6 Hadzisejdic I, Simat M, Bosak A , et al. Prevalence of human papillomavirus genotypes in cervical cancer and precursor lesions.Coll Antropol. 2006 ,30(4):879-883.
7 Kanjanavirojkul N, Pairojkul C, Yuenyao P, et al. Risk factors and histological outcome of abnormal cervix with human papilloma infection in northeastern Thai-women. Asian Pac J Cancer Prev.2006 ,7(4): 567-570.
8 Moscicki AB, SchiffmanM, KjaerS, et al.Chapter 5:Updating the natural history of HPV and anogenital cancer. Vaccine, 2006, 24 suppl3:S42-51.
9 Monnier-Benoit S, Mauny F, Riethmuller D, et al. Immunohistochemical analysis of CD4+ and CD8+T cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix.Gynecol Oncol, 2006,102:22-31
10 MatsumotoK,Yasugi T,OkiA,et al.IgGantibodies to HPV 16,52,58 and 6Ll-capsids and spontaneous regretssion of cervical intraepithelial neoplasia.Cancer Left,2006,231:309-313
11 Stanley M.Immune responses to huan papillomavirus.Vccine,2006,24Suppl 1:s16-22
12 赵方辉,马俊飞,乔友林,等.人乳头状瘤病毒DNA载量与子宫颈病变的关系.中华流行病学杂志,2004,25(11):921-924
13 Song SH,SH,LeeJK,Seok OS,et al.The relationgship between cytokines and HPV16,HPV16 E6,E7,and high risk HPV Viral load in the utrine cervix.Gynecol Oncoi,2007,104(3):732-738.
14 Depuydt CE,Benoy IH,Bailleu]EJ,et al.Improved endocervical sampling and HPV viral load detection by CercexBrush Combi,Cytopathology,2006,17(6):374-381
15 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
16 Koutsky LA,Ault KA,Wheeler CM,et al.A controlled trial of a humanpapillomavirus type 16 vaccine.N EngI J Med2002;347:1645-1651.
17 Harper DM,Franco EL,Wheeler C,et al.Efficacy of a bivalent L1virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women:a randomised controlled trial.Lancet 2004;364:1757-1765.
18 Villa LL,Costa RL,Petta CA,et al.Prophylactic quadrivalent human papiiiomavirus(types 6,11,16,and 18) L1 virus-like particle vaccine in young women:a randomised double-blind placebo-controlled multicentre phase Ⅱ efficacy trial.Lancet Oncol.2005;6:271-278.
19 Smith J,Lindsay L,Keys J,Hoots B,Winer R,Franceschi Set al.HPV type distribution in invasive cerviocal cancer and high-grade cervical neoplasia:an update of meta-analyses and identification of global data-gaps.Int J Cancer.2006.Personal communication,paper in press.
20 Solomon DSchiffman M,Tarone R.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial.J Natl Cancer Inst.2001,93(4):293-299.
21 Hernandez DM,OrnelasBM,Guido JM,et al.Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexicon women.Gynecol 0ncoi,2003,90:310-317.
22 Dalstein V,Riethmuller D,Preter JL,et al.Persistence and load of high-risk HPV are predictor for development of high-grade cervical lesions:a longitudinal French cohort study.Int J Cancer,2003,106:396-403.
23 Schlecht NF,Trevisan A,Duarte-Franco E,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia.Int J Cancer,2003,103:519-524.
24 黄志红,钱德英,王丁,等.人乳头状瘤病毒负荷量与宫颈癌以及宫颈癌前病变的相关研究.中国妇幼保健,2006,21(11):1557一1559.
25 Lorincz AT,Castle PE,Sherman ME,et al.Viral load of human papillomavirus and risk of CIN3 or cervical cancer.Lancet,2002,360:228-229.
26 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
27 Rousseau MN,Costes V,Konate I,et al Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso.J Med Virol,2007,79(6):766-770.
28 Schiffman M,Herrero R,Hildesheim A,et al.HPV DNA testing in cervical cancer screening:results from women in a high risk province of Costa Rica.JAMA 2000,283(1):87-93.
29 Wright TC Jr Denny L,Kuhn L et al.HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.JAMA,2000,283(1):81-86.
30 Cuaick J,Clavel C,Petry KU,et al.Overview of the European and North American Studies on HPV testing in Primary cervical screening,lnt J Cancer,2006,119:105-142
31 赵方辉 李楠 马俊飞,等.山西省襄垣县妇女人乳头状瘤病毒感染与宫颈癌关系的研究.中华流行病学杂志,2001,22(5):375-377
32 Ruud LM Bekkers Alazawil WF,Robertsl I,et al.Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer.Rev Med Virol,2004,14:95-104
33 Kololiopoulos G,Arvcn M,Martin-Hirsch P,et al.Diagnostic accuracy of human papillomavirus testing in primary cervical screening:a systematic review and meta-analysis of non-randomized studies.Gynecol Oncol,2007,104(1):232-246
34 Apgar BS,Zoschnick L,Wright TC Jr.The 2001 Bethesda System terminology.Am Fam Physician,2003,68:1992-8.
35 Pirog EC,Erroll M,Harigopal M,et al.Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems.Arch Pathol Lab Med,2004,128:527-32.
36 Cox JT.Management of women with cervical cytology interpreted as ASC-US or as ASC-H.Clin Obstet Gynecol,2005,48:160-177.
37 Simsir A,Ioffe O,Sun P,et al.Effect of Bethesda 2001 on reporting of atypical squamous cells(ASC) with special emphasis on atypical squamous cells-cannot rule out high grade(ASC-H).Diagn Cytopathol,2006,34:62-69
38 Alli PM,Ali SZ:Atypical squamous cells of undetermined significance -rule out high-grade squamous intraepithelial lesion:cytopathlogic characteristics and clinical correlates.Diagn Cytopathol 2003,28(6):308-12
39 Stany MP,Bius MA,Reed EJ,et al.The prevalence of HR-HPV in ASC-US pap smears:A military population study.Gynecol Oncol,2006,101:82-85
40 卞美璐,陈庆云,张小燕,等.对宫颈细胞学诊断意义未明的不典型鳞状细胞患者的临床管理.中华医学杂志,2006,86(33):2339-2342
41 Ruud LM Bekkers,et al.Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer.Rev Med Virol,2004,14;95
42 Shalinl I Kulasingam,et al.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities coparison of sensitivity,sepecificity,and frecuency of referral.JAMA,2002,288;1749
43 Thomas C Wright Jr,et al.Interim guidance for the use of human papillomavirus DNA test as an adjunct to cervical cytology for screening.Obstet Gynecol,2004,103:304
44 MMichele Manos,et al.Identifying women with cervical neoplasia.JAMA,1999,281:1065
45 Paraskevaidis E,et al.The role of HPV DNA testing in the follow-up period after treatment for CIN:A syste matic review of the literature.Can Treat Rew,2004,30:205
46 Poljak M,Marin IJ,Seme K,et alHybrid Capture Ⅱ HPV Test detects at lease 15 human papillomvirus genotypes not included in its current high-risk probe cocktail.J Clin Virol,2002,25 Suppl 3:S89-S97.
47 Wentzensen N,Vinokurova S,Doeberitz MK,et al.Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract.Cancer Research2004,64:3878-3884.
48 Pettl MR,Alazawil WF,Robertsl I,et al.Acquisiton of high-level chromosomal instability is associated with integration of HPV type 16in cervical keratinocytes.Cancer Research,2004,64:1359-1368.
49 Si HX,Tsao SW,Poon CS,et al.Physical status of HPV-16 in esophageal squamous cell carcinoma.J Clin Virol,2005,32:19-23.
50 Dell G,Gaston K.Human papillomaviruses and their role in cervical cancer.Cell Mol Life Sci,2001,58(12-13):1923-1942.
51 陶萍萍 卞美璐 欧华,等.导流杂交基因芯片技术在人乳头状瘤病毒检测中应用的研究.中华妇产科杂志,2006,6(1):44-47
52 王敏,王方金,吴健,等.低密度基因芯片技术检测人乳头瘤病毒基因型.中山大学学报,2006,7(4):431-434
53 van Den Brule AJ,Po IR,Fransen Daalmeijer N,et al.GPS+/6+ PCR followed by reverse line blot analysis enables rapid and high throughput identification of human papillomavirus genotypes.J Clin Microbiol,2002,40(3):779-787.
54 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method.Cancer,2003,97(7):1672-1680.
55 Kim CJ,Jeong JK,Park M,et al.HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions.Gynecol Oncol 2003,89(2):210-217.
56 Clifford GM,Smith JS,Plummer M,et al.Human Papillomavirus types in invasive cervical cancer worldwide:a meta-analysis.Br J Cancer,2003,88(1):63-73.
57 Smith,et al.unpublished
58 Munoz N,Bosch FX,Castellsague X,et al.Against which human papillomavirus types shall we vaccinate and screen?The international perspective.Int J Cancer,2004,111(2):278-285.
59 Huang LW,Chao SL,Hwang JL,et al.Hunam Papillomavirus-31-Related types predict better survival in cervical carcinoma.Cancer,2004,100(2):327-334.
60 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method.Cancer,2003,97(7):1672-80.
61 Frish M,Alazawil WF,Robertsl I,et al.Variants of squqamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.Cancer Res 1999,59(3):753-757.
62 Choi BS,Kim SS,Yun H,et al.Distinctive distribution of HPVl6 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers.J Med Virol.200779(4):426-430
63 Shai A,Brake T,Somoza C,et al.The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.Cancer Res.2007,67(4):1626-1635.
64 Hellberg D,Nilsson S,Grad A,et al.Behavior of cervical intraepithelial neoplasia(CIN) associated with various human papillomavirus(HPV) types.Arch Gynecol Obstet,1993,252(3):119-128.
65 Khan ML,Castle PE,Lorincz AT,at al.J Natl Cancer Inst,2005,97(14):1072-1079
66 Lo WK,Wong YF,Chan KM,et al.Prevalence of human papillomavirus in cervical cancer:a multicenter study in China.Int J Cancer,2002,100(3):327-331.
67 Herrero R,Hildesheim A,Bratti C,et al.Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.J Natl Cancer Inst,2000,92(6):464-474.
68 刘宝印,李洁,De Villier EM,等.我国人乳头瘤病毒58亚型感染与宫颈癌的关系.中华实验和临床病毒学杂志,1996,10(2)::118-121.
69 J ouThe prognosis of the HPV infected cervical lesions after followed up for a term.J Saitama Med school,2003,30(2):147-153.
1.Working group on the evaluation of cancer-preventive strategies.Iarc Handbooks of Cancer Prevention Yol 10:Cervix Cancer Screening.Lyon,France:IARC Press;2005
2.Bohmer G,van den Brule AJ,Brummer O,et al.No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasiagrade 3 or invasive primary cancer of the uterine cervixamong 511 patients.Am J Obstet Gynecol,2003:189:118-120.3.Munoz N,Bosch FX,de Sanjoseet al.International agency for research on cancer multicenter cervical cancer study group.Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med2003,348:517-527.
4.Agosti JM,Goldie SJ.Introducing HPV vaccine in developing countries-key challenges and issues.N Engl J Med.2007 356(19):1908-10.
5.Allred S,Cox JT,Mahoney M.HPV prevention and the promise of the new vaccines.J Am Acad Nurse Pract.2006;18 Suppl 2:1-11.
6.Frish M,Alazawil WF,Robertsl I,et al.Yariants of squqamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.Cancer Res 1999,59(3):753-757
7.Choi BS,Kim SS,Yun H,et al.Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers.J Med Virol.200779(4):426-30
8.Shai A,Brake T,Somoza C,et al.The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.Cancer Res.2007,67(4):1626-1635.
9.叶寿山,盛晓蓉,王萍等。莪术油软胶囊抗病毒作用的研究。中药药理作用与临床,2005,21(3):20-23.
10.程志强,贾立群,杜秀平等。抗癌消水膏对人肺腺癌 A549 细胞裸小鼠胸膜转移模型的影响。癌症进展杂志,2003,1(2):157-160.
11.王茂盛。中药学。北京:科学技术出版社,2001,263-264.
12.何必立,吕宾,徐毅,等。温郁金对胃癌细胞的抑制作用及其对血管内皮生长因子表达的影响。中医药学刊,2006,24(9):1741-1743
13.盛辉,苑春莉,王医术。莪术油对肺癌SPC-A4细胞株的体外抑制作用。江西中医学院学报,2006,18(5):51-52
14.宋利琼,张昌菊。莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响。上海中医药杂志,2006,40(5):68-69
15.赵毅,杨汝刚,罗民。莪术油的药理作用及临床应用研究进展。实用中医内科杂志。2006,20(2):125-126
16.单厚昌,马伟光,高中祖。我国天然抗肿瘤药的研究进展[J]。现代中西医结合杂志,2005,14(6):825-827.
17.沈铿。宫颈上皮内病变治疗方法的选择。中华医学杂志,2006,86(5):291-294
18.叶寿山,盛晓蓉,王萍等。莪术油软胶囊抗病毒作用的研究[J]。中药药理作用与临床,2005,21(3):20-23.
19.冯宏业,葛朝莉。冰片对癫痫患者血清和脑脊液卡马西平药物浓度的作用[J]。海南医学,2005,16(6):11-12.
20.刘朝奇,韩广州,李昆等。人巨细胞病毒协同人乳头瘤病毒16型诱导宫颈上皮细胞癌变的研究[J]。中华病理学杂志,1999,28(1):24-27.
21.Park C,Kim GY,Kim GD et al.Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24cells[J].Oncol Rep,200615(5):1225-31
22.Holy JM.Curcumin disrupts mitotic spindle structrure and induces micronucleation in MCF-Tbreast cancer cells[J].Mutat Res,2002518(1):71-84
23.eFilippis RA,Goodwin EC,Wu LL,et al.Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation,senescence,and apoptosis in HeLa cervical carcinoma cells..3 Virology,2003,77(2):1551-1563.
24.Cui SX,Qu XJ,Xie YY,et al.Curcumin inhibits telomerase activity in human cancer cell lines.Int J Mod Med,2006,18(2):227-231.
25.Hartwell LH,Kastan MB.Cell cycle control and cancer.Science,1994,266(5192):1821
26.赵华,汤为学.莪术油对人子宫内膜癌细胞株RL-92-L 抑制作用的体外研究.实用妇产科杂志,2006,22(3):158-160
1 Bohmer G, van den Brule AJ, Brummer O, et al. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol, 2003:189:118-120.
2 Clifford GM, smith JS. Plummer M, et al.Human papillomavirus types in invasive cervical cancer worldwide: a meta analysis. Br J Cancer ,2003,88:63-73.
3 Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med, 1992, 327(18):1272-8.
4 Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst, 1995, 87(18):1365-71.
5 Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.Int J Cancer ,1995,61(3):306-11.
6 Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study Lancet , 1999, 354(9172):20-5.
7 Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 1998, 338(7):423-8.
8 Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a humanpapillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
9 Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
10 Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278
11 MunozN, Bosch FX, de-San jose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348 (6):518-27.
12 Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005; 4:204-209
13 Oliveira LH, Rodrigues EV, lopes AP, et al.HPV16 detection in cervical lesions, physical state of viral DNA and changes in P53 gene. Sao Paulo Med J,2003, 121(2):1516-1521.
14 Moscicki AB, SchiffmanM, KjaerS, et al. Chapter 5:Updating the natural history of HPV and anogenital cancer. Vaccine, 2006, 24 suppl3:S42-51.
15 Concaves MA, Donadi EA. Immune cellular response to HPV:current concepts.Braz J Infect Dis, 2004,8:1-9.
16 Monnier-Benoit S, Mauny F, Riethmuller D, et al. Immunohistochemical analysis of CD4+ and CD8+T cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol Oncol, 2006,102:22-31.
17 Rocha-Zavaleta L, Ambrosio JP, Mora-Garcia Mde L, et al.Detection of antibodyes agaist a human papillomavirus(HPV) type 16 peptide that difeerentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J Gen Virol, 2004, 85:2643-2650.
18 Trimble CL, Piantadosi S, Gravitt P, et al.Spontanenous regression of high-grade cervical dysplasia:effects of human papillomavirus type and HLA phenotype. Clin Cancer Res, 2005,11:4717-4723.
19 Sastre-Garau X,Cartier I,Jourdan-Da Silva N,et al.Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRBL13 genotype.Obstet Gynecol,2004,104:751-755
20 Durst,Costa RL,Petta CA,et al.Molecular and cytogentic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA.Oncogene,1987,1(3):251-256
21 Hernandez DM,OrnelasBM,Guido JM,et al.Association between high-risk human papillomavirus DNAload and precursor lesions of cervical cancer in Mexicon women.Gynecol 0ncoi,2003,90:310-317.
22 Dalstein V,Riethmuller D,Preter JL,et al.Persistence and load of high-risk HPV are predictor for development of high-grade cervical lesions:a longitudinal French cohort study,lnt J Cancer,2003,106:396-403.
23 Schlecht NF,Trevisan A,Duarte-Franco E,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia.Int J Cancer,2003,103:519-524.
24 黄志红,钱德英,王丁,等.人乳头状瘤病毒负荷量与宫颈癌以及宫颈癌前病变的相关研究.中国妇幼保健,2006,21(11):1557-1559.
25 Lorincz AT,Castle PE,Sherman ME,et al.Viral load of human papillomavirus and risk of CIN3 or cervical cancer.Lancet,2002,360:228-229.
26 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
27 Rousseau MN,Costes V,Konate I,et al Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso.J Med Virol,2007,79(6):766-770.
28 Strickler HD,Tsao SW,Poon CS,et al.Human pappilomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003, 95(14):1062-71
29 Solomon D ,Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial. J Natl Cancer Inst. 2001, 93(4):293-99.
30 Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening :results from women in a high risk province of Costa Rica. JAMA , 2000, 283 (1): 87-93.
31 Wright TC Jr , Denny L, Kuhn L , et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA, 2000, 283 (1):81-6.
32 Clavel C, Masure M, Bory JP, et al. Hunam papillomavirus testing in primary screening for the detection of high-grade cervical lesions:a study of 7932 women. Br J Cancer, 2001, 84(12):1616-23.
33 Castle PE, Lorincz AT, Mielzynska-Lohnas I, et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol, 2002, 40(3):1088-90.
34 Poljak M, Marin IJ, Seme K, et al .Hybrid Capture IIHPV Test detects at lease 15 human papillomvirus genotypes not included in its current high-risk probe cocktail. J Clin Virol, 2002,25 Suppl 3: S89-97.
35 Sandri TS, Lentana P, Benini E, et al. Comparison of the Digene HC2 Assay and the Roche AMPLICOR human pappilomavirus test for detection of HR-HPV genotype in cervical samples. J Clin Microbiol,2006, 44(6):2141-2146
36 Albrecht V, Chevallier A, Magnone V, et al.Easy and fast detect ion and genotyping of jigh-risk human papillomavirus by dedicated DNA microarrays. J Virol Med, 2006,137236-244
37 Peedicayil A, Abraham P, Sathish N, et al. Human pappilomavirus genotype s associated with cervical neoplasia in India.2006,16:1591-1595
38 Wentzensen N,Vinokurova $,Doeberitz MK,et al.Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract.Cancer Research2004,64:3878-3884.
39 Pettl MR,Alazawil WF,Robertsl I,et al.Acquisiton of high-level chromosomal instability is associated with integration of HPV type 16in cervical keratinocytes.Cancer Research,2004,64:1359-1368.
40 Si HX,Tsao SW,Poon CS,et al.Physical status of HPV-16 in esophageal squamous cell carcinoma.J Clin Virol,2005,32:19-23.
41 刘继峰,马烈,郭劲柏,等.尖锐湿疣人乳头瘤病毒的基因分型.中国皮肤性病杂志,2001,15(1):2-3.
42 Hsu TM,Chen X,Dnao S,et al.Universal SNP genotyping assay with fluorescence polarization detection.Bio techniques2001,31(3):560-8.
43 Zhang J,Yah X,Sun J,et al.A high throughout assay for human papillomavirus genotypes with fluorescence polarization.Chin Med J(Engl),2003 116(8):1137-40.
44 王金花,Bakkers J,Melchers W JG.子宫颈刮片中人乳头瘤病毒的基因分型.中华实验和临床病毒学杂志,1999,13(1):9-12.
45 Peyton CL,Gravitt PE,Hunt WC,et al.Determinants of genital human papillomavirus detection a US Population.J Infect Dis 2001,183(11):1554-64.
46 van Den Brule AJ,Po IR,Fransen Daalmeijer N,etal.GPS+/6+ PCR followed by reverse line blot analysis enables rapid and high throughput identification of human papillomavirus genotypes.J Clin Microbiol,2002,40(3):779-87.
47 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method. Cancer, 2003 , 97(7):1672-80
48 CuizickJ, Gravitt PE, Hunt WC, et al. Human papillomavirus in primary cervical screening. Lancet, 1995, 345:1533-1536
49 WrightTC, Jr, SchiffmanM, SolomonD, etal. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. ObstetGynecol, 2004,103(2);304-310
50 Petry KU, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in germany: Results for 8466 patients. Br J Cancer, 2003, 88: 1570-1577
51 Shalinl I Kulasingam, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities coparison of sensitivity, sepecificity, and frecuency of referral. JAMA, 2002, 288:1749-1756
52 Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen?The international perspective. Int J Cancer, 2004,111(2): 278-85.
53 Clifford GM, Smith JS, Plummer M, et al. Human Papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer,2003,88(1):63-73.
54 Smith , unpublised
55 Choi YD, Jung W W, Nam JH, et al. Detection of HPV genotypes in cervical lesions by HPV DNA chip and sequencing. Gynecol Onco, 2005, 98(3):369-375
56 Hellberg D, Nilsson S, Grad A, et al. Behavior of cervical intraepithelial neoplasia (CIN) associated with various human papillomavirus (HPV) types. Arch Gynecol Obstet, 1993,252(3):119-28.
57 Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.J Natl Cancer Inst,1995,87(18):1365-71.
58 Khan ML,Castle PE,Lorincz AT,at al.J Natl Cancer Inst,2005,97(14):1072-1079
59 Apgar BS,Zoschnick L,Wright TC Jr.The 2001 Bethesda System terminology.Am Fam Physician,2003,68:1992-8.
60 Pirog EC,Erroll M,Harigopal M,et al.Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems.Arch Pathol Lab Med,2004,128:527-32.
61 Cox JT.Management of women with cervical cytology interpreted as ASC-US or as ASC-H.Clin Obstet Gynecol,2005,48:160-77.
62 Simsir A,Ioffe O,Sun P,et al.Effect of Bethesda 2001 on reporting of atypical squamous cells(ASC) with special emphasis on atypical squamous cells-cannot rule out high grade(ASC-H).Diagn Cytopathol,2006,34:62-6
63 Stany MP,Bius MA,Reed EJ,et al.The prevalence of HR-HPV in ASC-US pap smears:A military population study.Gynecol Oncol,2006,101:82-85
64 卞美璐,陈庆云,张小燕,等.对宫颈细胞学诊断意义未明的不典型鳞状细胞患者的临床管理.中华医学杂志,2006,86(33):2339-2342
65 Harper DM,Franco EL,Wheeler CM,et al.Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:follow-up from a randomised control trial.Lancet.2006,367(9518):1247-1255
66 Andrawiss M.Cervical cancer vaccines available in 2007.Drug Discov Today,2005,10(14):949-950.
67 Embers ME,Budgeon LR,Culp TD,et al.Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.Vaccine.2004 Jan 26;22(5-6):670-80.
68 De Marco F, Hallez S, Brulet JM, et al. DNA vaccines against HPV 16 E7 expressing tumour cells. Anticancer Res, 2003, 23: 1449-1454.
69 Kaufmann AM, Stem PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, A recombinant vaccinia virus expressing modified human papillomavirus (HPV) 16 and HPV 18 E6 and E7 genes in women with progressive cervical cancer. Clin Cancer Res, 2002, 8(12): 3676-3685.
70 Wakabayashi MT, Dasilva DM, Potkul RK, et al. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor revention. Intervirology, 2002,45: 300-307.
71 Wang J, Sampath A, Raychaudhuri P, et al. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV containing cervical tumor cells. Oncogene, 2001, 20(34):4740 4749
2 Blanchet JS, Sonnex C, Gough GW, et al. Local and systemic human papillomavirus type 6b-specific cellular immune responses in patients with recurrent genital warts. Viral Immunol. 2007,20(1):44-55.
3 Hagiwara M, Sasaki H, Matsuo K, et, al. Loop-mediated isothermal amplification method for detection of human papillomavirus type 6, 11, 16, and 18. J Med Viral. 2007, 79(5):605-615.
4 Gajewska M, Wielgos M, Kaminski P, et al. The occurrence of genital types of human papillomavirus in normal pregnancy and in pregnant renal transplant recipients. Neuro Endocrinol Lett. 2006 Aug;27(4) :529-534.
5 Tarkkanen J, Auvinen E, Nieminen P, et al. HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland.Acta Obstet Gynecol Scand. 2007;86(3):367-372.
6 Hadzisejdic I, Simat M, Bosak A , et al. Prevalence of human papillomavirus genotypes in cervical cancer and precursor lesions.Coll Antropol. 2006 ,30(4):879-883.
7 Kanjanavirojkul N, Pairojkul C, Yuenyao P, et al. Risk factors and histological outcome of abnormal cervix with human papilloma infection in northeastern Thai-women. Asian Pac J Cancer Prev.2006 ,7(4): 567-570.
8 Moscicki AB, SchiffmanM, KjaerS, et al.Chapter 5:Updating the natural history of HPV and anogenital cancer. Vaccine, 2006, 24 suppl3:S42-51.
9 Monnier-Benoit S, Mauny F, Riethmuller D, et al. Immunohistochemical analysis of CD4+ and CD8+T cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix.Gynecol Oncol, 2006,102:22-31
10 MatsumotoK,Yasugi T,OkiA,et al.IgGantibodies to HPV 16,52,58 and 6Ll-capsids and spontaneous regretssion of cervical intraepithelial neoplasia.Cancer Left,2006,231:309-313
11 Stanley M.Immune responses to huan papillomavirus.Vccine,2006,24Suppl 1:s16-22
12 赵方辉,马俊飞,乔友林,等.人乳头状瘤病毒DNA载量与子宫颈病变的关系.中华流行病学杂志,2004,25(11):921-924
13 Song SH,SH,LeeJK,Seok OS,et al.The relationgship between cytokines and HPV16,HPV16 E6,E7,and high risk HPV Viral load in the utrine cervix.Gynecol Oncoi,2007,104(3):732-738.
14 Depuydt CE,Benoy IH,Bailleu]EJ,et al.Improved endocervical sampling and HPV viral load detection by CercexBrush Combi,Cytopathology,2006,17(6):374-381
15 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
16 Koutsky LA,Ault KA,Wheeler CM,et al.A controlled trial of a humanpapillomavirus type 16 vaccine.N EngI J Med2002;347:1645-1651.
17 Harper DM,Franco EL,Wheeler C,et al.Efficacy of a bivalent L1virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women:a randomised controlled trial.Lancet 2004;364:1757-1765.
18 Villa LL,Costa RL,Petta CA,et al.Prophylactic quadrivalent human papiiiomavirus(types 6,11,16,and 18) L1 virus-like particle vaccine in young women:a randomised double-blind placebo-controlled multicentre phase Ⅱ efficacy trial.Lancet Oncol.2005;6:271-278.
19 Smith J,Lindsay L,Keys J,Hoots B,Winer R,Franceschi Set al.HPV type distribution in invasive cerviocal cancer and high-grade cervical neoplasia:an update of meta-analyses and identification of global data-gaps.Int J Cancer.2006.Personal communication,paper in press.
20 Solomon DSchiffman M,Tarone R.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial.J Natl Cancer Inst.2001,93(4):293-299.
21 Hernandez DM,OrnelasBM,Guido JM,et al.Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexicon women.Gynecol 0ncoi,2003,90:310-317.
22 Dalstein V,Riethmuller D,Preter JL,et al.Persistence and load of high-risk HPV are predictor for development of high-grade cervical lesions:a longitudinal French cohort study.Int J Cancer,2003,106:396-403.
23 Schlecht NF,Trevisan A,Duarte-Franco E,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia.Int J Cancer,2003,103:519-524.
24 黄志红,钱德英,王丁,等.人乳头状瘤病毒负荷量与宫颈癌以及宫颈癌前病变的相关研究.中国妇幼保健,2006,21(11):1557一1559.
25 Lorincz AT,Castle PE,Sherman ME,et al.Viral load of human papillomavirus and risk of CIN3 or cervical cancer.Lancet,2002,360:228-229.
26 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
27 Rousseau MN,Costes V,Konate I,et al Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso.J Med Virol,2007,79(6):766-770.
28 Schiffman M,Herrero R,Hildesheim A,et al.HPV DNA testing in cervical cancer screening:results from women in a high risk province of Costa Rica.JAMA 2000,283(1):87-93.
29 Wright TC Jr Denny L,Kuhn L et al.HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.JAMA,2000,283(1):81-86.
30 Cuaick J,Clavel C,Petry KU,et al.Overview of the European and North American Studies on HPV testing in Primary cervical screening,lnt J Cancer,2006,119:105-142
31 赵方辉 李楠 马俊飞,等.山西省襄垣县妇女人乳头状瘤病毒感染与宫颈癌关系的研究.中华流行病学杂志,2001,22(5):375-377
32 Ruud LM Bekkers Alazawil WF,Robertsl I,et al.Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer.Rev Med Virol,2004,14:95-104
33 Kololiopoulos G,Arvcn M,Martin-Hirsch P,et al.Diagnostic accuracy of human papillomavirus testing in primary cervical screening:a systematic review and meta-analysis of non-randomized studies.Gynecol Oncol,2007,104(1):232-246
34 Apgar BS,Zoschnick L,Wright TC Jr.The 2001 Bethesda System terminology.Am Fam Physician,2003,68:1992-8.
35 Pirog EC,Erroll M,Harigopal M,et al.Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems.Arch Pathol Lab Med,2004,128:527-32.
36 Cox JT.Management of women with cervical cytology interpreted as ASC-US or as ASC-H.Clin Obstet Gynecol,2005,48:160-177.
37 Simsir A,Ioffe O,Sun P,et al.Effect of Bethesda 2001 on reporting of atypical squamous cells(ASC) with special emphasis on atypical squamous cells-cannot rule out high grade(ASC-H).Diagn Cytopathol,2006,34:62-69
38 Alli PM,Ali SZ:Atypical squamous cells of undetermined significance -rule out high-grade squamous intraepithelial lesion:cytopathlogic characteristics and clinical correlates.Diagn Cytopathol 2003,28(6):308-12
39 Stany MP,Bius MA,Reed EJ,et al.The prevalence of HR-HPV in ASC-US pap smears:A military population study.Gynecol Oncol,2006,101:82-85
40 卞美璐,陈庆云,张小燕,等.对宫颈细胞学诊断意义未明的不典型鳞状细胞患者的临床管理.中华医学杂志,2006,86(33):2339-2342
41 Ruud LM Bekkers,et al.Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer.Rev Med Virol,2004,14;95
42 Shalinl I Kulasingam,et al.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities coparison of sensitivity,sepecificity,and frecuency of referral.JAMA,2002,288;1749
43 Thomas C Wright Jr,et al.Interim guidance for the use of human papillomavirus DNA test as an adjunct to cervical cytology for screening.Obstet Gynecol,2004,103:304
44 MMichele Manos,et al.Identifying women with cervical neoplasia.JAMA,1999,281:1065
45 Paraskevaidis E,et al.The role of HPV DNA testing in the follow-up period after treatment for CIN:A syste matic review of the literature.Can Treat Rew,2004,30:205
46 Poljak M,Marin IJ,Seme K,et alHybrid Capture Ⅱ HPV Test detects at lease 15 human papillomvirus genotypes not included in its current high-risk probe cocktail.J Clin Virol,2002,25 Suppl 3:S89-S97.
47 Wentzensen N,Vinokurova S,Doeberitz MK,et al.Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract.Cancer Research2004,64:3878-3884.
48 Pettl MR,Alazawil WF,Robertsl I,et al.Acquisiton of high-level chromosomal instability is associated with integration of HPV type 16in cervical keratinocytes.Cancer Research,2004,64:1359-1368.
49 Si HX,Tsao SW,Poon CS,et al.Physical status of HPV-16 in esophageal squamous cell carcinoma.J Clin Virol,2005,32:19-23.
50 Dell G,Gaston K.Human papillomaviruses and their role in cervical cancer.Cell Mol Life Sci,2001,58(12-13):1923-1942.
51 陶萍萍 卞美璐 欧华,等.导流杂交基因芯片技术在人乳头状瘤病毒检测中应用的研究.中华妇产科杂志,2006,6(1):44-47
52 王敏,王方金,吴健,等.低密度基因芯片技术检测人乳头瘤病毒基因型.中山大学学报,2006,7(4):431-434
53 van Den Brule AJ,Po IR,Fransen Daalmeijer N,et al.GPS+/6+ PCR followed by reverse line blot analysis enables rapid and high throughput identification of human papillomavirus genotypes.J Clin Microbiol,2002,40(3):779-787.
54 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method.Cancer,2003,97(7):1672-1680.
55 Kim CJ,Jeong JK,Park M,et al.HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions.Gynecol Oncol 2003,89(2):210-217.
56 Clifford GM,Smith JS,Plummer M,et al.Human Papillomavirus types in invasive cervical cancer worldwide:a meta-analysis.Br J Cancer,2003,88(1):63-73.
57 Smith,et al.unpublished
58 Munoz N,Bosch FX,Castellsague X,et al.Against which human papillomavirus types shall we vaccinate and screen?The international perspective.Int J Cancer,2004,111(2):278-285.
59 Huang LW,Chao SL,Hwang JL,et al.Hunam Papillomavirus-31-Related types predict better survival in cervical carcinoma.Cancer,2004,100(2):327-334.
60 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method.Cancer,2003,97(7):1672-80.
61 Frish M,Alazawil WF,Robertsl I,et al.Variants of squqamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.Cancer Res 1999,59(3):753-757.
62 Choi BS,Kim SS,Yun H,et al.Distinctive distribution of HPVl6 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers.J Med Virol.200779(4):426-430
63 Shai A,Brake T,Somoza C,et al.The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.Cancer Res.2007,67(4):1626-1635.
64 Hellberg D,Nilsson S,Grad A,et al.Behavior of cervical intraepithelial neoplasia(CIN) associated with various human papillomavirus(HPV) types.Arch Gynecol Obstet,1993,252(3):119-128.
65 Khan ML,Castle PE,Lorincz AT,at al.J Natl Cancer Inst,2005,97(14):1072-1079
66 Lo WK,Wong YF,Chan KM,et al.Prevalence of human papillomavirus in cervical cancer:a multicenter study in China.Int J Cancer,2002,100(3):327-331.
67 Herrero R,Hildesheim A,Bratti C,et al.Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.J Natl Cancer Inst,2000,92(6):464-474.
68 刘宝印,李洁,De Villier EM,等.我国人乳头瘤病毒58亚型感染与宫颈癌的关系.中华实验和临床病毒学杂志,1996,10(2)::118-121.
69 J ouThe prognosis of the HPV infected cervical lesions after followed up for a term.J Saitama Med school,2003,30(2):147-153.
1.Working group on the evaluation of cancer-preventive strategies.Iarc Handbooks of Cancer Prevention Yol 10:Cervix Cancer Screening.Lyon,France:IARC Press;2005
2.Bohmer G,van den Brule AJ,Brummer O,et al.No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasiagrade 3 or invasive primary cancer of the uterine cervixamong 511 patients.Am J Obstet Gynecol,2003:189:118-120.3.Munoz N,Bosch FX,de Sanjoseet al.International agency for research on cancer multicenter cervical cancer study group.Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med2003,348:517-527.
4.Agosti JM,Goldie SJ.Introducing HPV vaccine in developing countries-key challenges and issues.N Engl J Med.2007 356(19):1908-10.
5.Allred S,Cox JT,Mahoney M.HPV prevention and the promise of the new vaccines.J Am Acad Nurse Pract.2006;18 Suppl 2:1-11.
6.Frish M,Alazawil WF,Robertsl I,et al.Yariants of squqamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.Cancer Res 1999,59(3):753-757
7.Choi BS,Kim SS,Yun H,et al.Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers.J Med Virol.200779(4):426-30
8.Shai A,Brake T,Somoza C,et al.The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.Cancer Res.2007,67(4):1626-1635.
9.叶寿山,盛晓蓉,王萍等。莪术油软胶囊抗病毒作用的研究。中药药理作用与临床,2005,21(3):20-23.
10.程志强,贾立群,杜秀平等。抗癌消水膏对人肺腺癌 A549 细胞裸小鼠胸膜转移模型的影响。癌症进展杂志,2003,1(2):157-160.
11.王茂盛。中药学。北京:科学技术出版社,2001,263-264.
12.何必立,吕宾,徐毅,等。温郁金对胃癌细胞的抑制作用及其对血管内皮生长因子表达的影响。中医药学刊,2006,24(9):1741-1743
13.盛辉,苑春莉,王医术。莪术油对肺癌SPC-A4细胞株的体外抑制作用。江西中医学院学报,2006,18(5):51-52
14.宋利琼,张昌菊。莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响。上海中医药杂志,2006,40(5):68-69
15.赵毅,杨汝刚,罗民。莪术油的药理作用及临床应用研究进展。实用中医内科杂志。2006,20(2):125-126
16.单厚昌,马伟光,高中祖。我国天然抗肿瘤药的研究进展[J]。现代中西医结合杂志,2005,14(6):825-827.
17.沈铿。宫颈上皮内病变治疗方法的选择。中华医学杂志,2006,86(5):291-294
18.叶寿山,盛晓蓉,王萍等。莪术油软胶囊抗病毒作用的研究[J]。中药药理作用与临床,2005,21(3):20-23.
19.冯宏业,葛朝莉。冰片对癫痫患者血清和脑脊液卡马西平药物浓度的作用[J]。海南医学,2005,16(6):11-12.
20.刘朝奇,韩广州,李昆等。人巨细胞病毒协同人乳头瘤病毒16型诱导宫颈上皮细胞癌变的研究[J]。中华病理学杂志,1999,28(1):24-27.
21.Park C,Kim GY,Kim GD et al.Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24cells[J].Oncol Rep,200615(5):1225-31
22.Holy JM.Curcumin disrupts mitotic spindle structrure and induces micronucleation in MCF-Tbreast cancer cells[J].Mutat Res,2002518(1):71-84
23.eFilippis RA,Goodwin EC,Wu LL,et al.Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation,senescence,and apoptosis in HeLa cervical carcinoma cells..3 Virology,2003,77(2):1551-1563.
24.Cui SX,Qu XJ,Xie YY,et al.Curcumin inhibits telomerase activity in human cancer cell lines.Int J Mod Med,2006,18(2):227-231.
25.Hartwell LH,Kastan MB.Cell cycle control and cancer.Science,1994,266(5192):1821
26.赵华,汤为学.莪术油对人子宫内膜癌细胞株RL-92-L 抑制作用的体外研究.实用妇产科杂志,2006,22(3):158-160
1 Bohmer G, van den Brule AJ, Brummer O, et al. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol, 2003:189:118-120.
2 Clifford GM, smith JS. Plummer M, et al.Human papillomavirus types in invasive cervical cancer worldwide: a meta analysis. Br J Cancer ,2003,88:63-73.
3 Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med, 1992, 327(18):1272-8.
4 Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst, 1995, 87(18):1365-71.
5 Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.Int J Cancer ,1995,61(3):306-11.
6 Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study Lancet , 1999, 354(9172):20-5.
7 Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 1998, 338(7):423-8.
8 Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a humanpapillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
9 Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
10 Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278
11 MunozN, Bosch FX, de-San jose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348 (6):518-27.
12 Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005; 4:204-209
13 Oliveira LH, Rodrigues EV, lopes AP, et al.HPV16 detection in cervical lesions, physical state of viral DNA and changes in P53 gene. Sao Paulo Med J,2003, 121(2):1516-1521.
14 Moscicki AB, SchiffmanM, KjaerS, et al. Chapter 5:Updating the natural history of HPV and anogenital cancer. Vaccine, 2006, 24 suppl3:S42-51.
15 Concaves MA, Donadi EA. Immune cellular response to HPV:current concepts.Braz J Infect Dis, 2004,8:1-9.
16 Monnier-Benoit S, Mauny F, Riethmuller D, et al. Immunohistochemical analysis of CD4+ and CD8+T cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol Oncol, 2006,102:22-31.
17 Rocha-Zavaleta L, Ambrosio JP, Mora-Garcia Mde L, et al.Detection of antibodyes agaist a human papillomavirus(HPV) type 16 peptide that difeerentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J Gen Virol, 2004, 85:2643-2650.
18 Trimble CL, Piantadosi S, Gravitt P, et al.Spontanenous regression of high-grade cervical dysplasia:effects of human papillomavirus type and HLA phenotype. Clin Cancer Res, 2005,11:4717-4723.
19 Sastre-Garau X,Cartier I,Jourdan-Da Silva N,et al.Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRBL13 genotype.Obstet Gynecol,2004,104:751-755
20 Durst,Costa RL,Petta CA,et al.Molecular and cytogentic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA.Oncogene,1987,1(3):251-256
21 Hernandez DM,OrnelasBM,Guido JM,et al.Association between high-risk human papillomavirus DNAload and precursor lesions of cervical cancer in Mexicon women.Gynecol 0ncoi,2003,90:310-317.
22 Dalstein V,Riethmuller D,Preter JL,et al.Persistence and load of high-risk HPV are predictor for development of high-grade cervical lesions:a longitudinal French cohort study,lnt J Cancer,2003,106:396-403.
23 Schlecht NF,Trevisan A,Duarte-Franco E,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia.Int J Cancer,2003,103:519-524.
24 黄志红,钱德英,王丁,等.人乳头状瘤病毒负荷量与宫颈癌以及宫颈癌前病变的相关研究.中国妇幼保健,2006,21(11):1557-1559.
25 Lorincz AT,Castle PE,Sherman ME,et al.Viral load of human papillomavirus and risk of CIN3 or cervical cancer.Lancet,2002,360:228-229.
26 Guo M,Sneige N,Silva EG,et al.Distribution and viral load of eight oncogenic types of human papillomavirus and HPV 16 intigration status in cervical intraepithelial neoplasmia and carcinoma.Mod Pathol,2007,20(2):256-266
27 Rousseau MN,Costes V,Konate I,et al Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso.J Med Virol,2007,79(6):766-770.
28 Strickler HD,Tsao SW,Poon CS,et al.Human pappilomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003, 95(14):1062-71
29 Solomon D ,Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial. J Natl Cancer Inst. 2001, 93(4):293-99.
30 Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening :results from women in a high risk province of Costa Rica. JAMA , 2000, 283 (1): 87-93.
31 Wright TC Jr , Denny L, Kuhn L , et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA, 2000, 283 (1):81-6.
32 Clavel C, Masure M, Bory JP, et al. Hunam papillomavirus testing in primary screening for the detection of high-grade cervical lesions:a study of 7932 women. Br J Cancer, 2001, 84(12):1616-23.
33 Castle PE, Lorincz AT, Mielzynska-Lohnas I, et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol, 2002, 40(3):1088-90.
34 Poljak M, Marin IJ, Seme K, et al .Hybrid Capture IIHPV Test detects at lease 15 human papillomvirus genotypes not included in its current high-risk probe cocktail. J Clin Virol, 2002,25 Suppl 3: S89-97.
35 Sandri TS, Lentana P, Benini E, et al. Comparison of the Digene HC2 Assay and the Roche AMPLICOR human pappilomavirus test for detection of HR-HPV genotype in cervical samples. J Clin Microbiol,2006, 44(6):2141-2146
36 Albrecht V, Chevallier A, Magnone V, et al.Easy and fast detect ion and genotyping of jigh-risk human papillomavirus by dedicated DNA microarrays. J Virol Med, 2006,137236-244
37 Peedicayil A, Abraham P, Sathish N, et al. Human pappilomavirus genotype s associated with cervical neoplasia in India.2006,16:1591-1595
38 Wentzensen N,Vinokurova $,Doeberitz MK,et al.Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract.Cancer Research2004,64:3878-3884.
39 Pettl MR,Alazawil WF,Robertsl I,et al.Acquisiton of high-level chromosomal instability is associated with integration of HPV type 16in cervical keratinocytes.Cancer Research,2004,64:1359-1368.
40 Si HX,Tsao SW,Poon CS,et al.Physical status of HPV-16 in esophageal squamous cell carcinoma.J Clin Virol,2005,32:19-23.
41 刘继峰,马烈,郭劲柏,等.尖锐湿疣人乳头瘤病毒的基因分型.中国皮肤性病杂志,2001,15(1):2-3.
42 Hsu TM,Chen X,Dnao S,et al.Universal SNP genotyping assay with fluorescence polarization detection.Bio techniques2001,31(3):560-8.
43 Zhang J,Yah X,Sun J,et al.A high throughout assay for human papillomavirus genotypes with fluorescence polarization.Chin Med J(Engl),2003 116(8):1137-40.
44 王金花,Bakkers J,Melchers W JG.子宫颈刮片中人乳头瘤病毒的基因分型.中华实验和临床病毒学杂志,1999,13(1):9-12.
45 Peyton CL,Gravitt PE,Hunt WC,et al.Determinants of genital human papillomavirus detection a US Population.J Infect Dis 2001,183(11):1554-64.
46 van Den Brule AJ,Po IR,Fransen Daalmeijer N,etal.GPS+/6+ PCR followed by reverse line blot analysis enables rapid and high throughput identification of human papillomavirus genotypes.J Clin Microbiol,2002,40(3):779-87.
47 An HJ,Cho NH,Lee SY,et al.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV) genotypes detected with the HPV DNA chip microarray method. Cancer, 2003 , 97(7):1672-80
48 CuizickJ, Gravitt PE, Hunt WC, et al. Human papillomavirus in primary cervical screening. Lancet, 1995, 345:1533-1536
49 WrightTC, Jr, SchiffmanM, SolomonD, etal. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. ObstetGynecol, 2004,103(2);304-310
50 Petry KU, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in germany: Results for 8466 patients. Br J Cancer, 2003, 88: 1570-1577
51 Shalinl I Kulasingam, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities coparison of sensitivity, sepecificity, and frecuency of referral. JAMA, 2002, 288:1749-1756
52 Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen?The international perspective. Int J Cancer, 2004,111(2): 278-85.
53 Clifford GM, Smith JS, Plummer M, et al. Human Papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer,2003,88(1):63-73.
54 Smith , unpublised
55 Choi YD, Jung W W, Nam JH, et al. Detection of HPV genotypes in cervical lesions by HPV DNA chip and sequencing. Gynecol Onco, 2005, 98(3):369-375
56 Hellberg D, Nilsson S, Grad A, et al. Behavior of cervical intraepithelial neoplasia (CIN) associated with various human papillomavirus (HPV) types. Arch Gynecol Obstet, 1993,252(3):119-28.
57 Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.J Natl Cancer Inst,1995,87(18):1365-71.
58 Khan ML,Castle PE,Lorincz AT,at al.J Natl Cancer Inst,2005,97(14):1072-1079
59 Apgar BS,Zoschnick L,Wright TC Jr.The 2001 Bethesda System terminology.Am Fam Physician,2003,68:1992-8.
60 Pirog EC,Erroll M,Harigopal M,et al.Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems.Arch Pathol Lab Med,2004,128:527-32.
61 Cox JT.Management of women with cervical cytology interpreted as ASC-US or as ASC-H.Clin Obstet Gynecol,2005,48:160-77.
62 Simsir A,Ioffe O,Sun P,et al.Effect of Bethesda 2001 on reporting of atypical squamous cells(ASC) with special emphasis on atypical squamous cells-cannot rule out high grade(ASC-H).Diagn Cytopathol,2006,34:62-6
63 Stany MP,Bius MA,Reed EJ,et al.The prevalence of HR-HPV in ASC-US pap smears:A military population study.Gynecol Oncol,2006,101:82-85
64 卞美璐,陈庆云,张小燕,等.对宫颈细胞学诊断意义未明的不典型鳞状细胞患者的临床管理.中华医学杂志,2006,86(33):2339-2342
65 Harper DM,Franco EL,Wheeler CM,et al.Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:follow-up from a randomised control trial.Lancet.2006,367(9518):1247-1255
66 Andrawiss M.Cervical cancer vaccines available in 2007.Drug Discov Today,2005,10(14):949-950.
67 Embers ME,Budgeon LR,Culp TD,et al.Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.Vaccine.2004 Jan 26;22(5-6):670-80.
68 De Marco F, Hallez S, Brulet JM, et al. DNA vaccines against HPV 16 E7 expressing tumour cells. Anticancer Res, 2003, 23: 1449-1454.
69 Kaufmann AM, Stem PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, A recombinant vaccinia virus expressing modified human papillomavirus (HPV) 16 and HPV 18 E6 and E7 genes in women with progressive cervical cancer. Clin Cancer Res, 2002, 8(12): 3676-3685.
70 Wakabayashi MT, Dasilva DM, Potkul RK, et al. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor revention. Intervirology, 2002,45: 300-307.
71 Wang J, Sampath A, Raychaudhuri P, et al. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV containing cervical tumor cells. Oncogene, 2001, 20(34):4740 4749